Risk factors for cardiac dysfunction in children on treatment for cancer at Kenyatta National Hospital, Nairobi by Shiroya-Wandabwa, M et al.
S52 East african MEdical Journal December 2009 (Supplement)
East African Medical Journal Vol. 86 (Supplement) December 2009
RISK FACTORS FOR CARDIAC DYSFUNCTION IN CHILDREN ON TREATMENT FOR CANCER AT KENYATTA 
NATIONAL HOSPITAL, NAIROBI
M. Shiroya-Wandabwa, MBChB, MMed (Paed), International Centre for AIDS Programs, Kenya, C. Yuko-Jowi, MBChB, 
MMed (Paed), Senior Lecturer, R. Nduati, MBChB, MMed (Paed.), Associate Professor, Department of Paediatrics and 
Child Health,  J. Githang’a, MBChB, MMed (Path), Senior Lecturer, Department of Human Pathology and D. Wamalwa, 
MBChB, MMed (Paed), Lecturer, Department of Paediatrics and Child Health, College of Health Sciences, University 
of Nairobi, P. O. Box 19676- 00202, Nairobi, Kenya
Requests for reprints to: Dr. M. Shiroya-Wandabwa, P. O. Box 29840-00202, Nairobi, Kenya
  
RISK FACTORS FOR CARDIAC DYSFUNCTION IN CHILDREN ON TREATMENT 
FOR CANCER AT KENYATTA NATIONAL HOSPITAL, NAIROBI  
 
M. SHIROYA-WANDABWA, C. YUKO-JOWI, R. NDUATI, J. GITHANG’A and D. WAMALWA
   
ABSTRACT
Objective: To determine the point prevalence of abnormal cardiac function and to assess 
the risk  factors for cardiac dysfunction  in paediatric oncology patients on treatment 
at Kenyatta National Hospital.
Design: Descriptive cross-sectional study with a nested case control.
Setting: Kenyatta National Hospital between February and April 2006.
Main outcome measures: Left ventricular dysfunction if ejection fraction (EF) <55% or 
fractional shortening (FS) <29% defined cases. Controls had EF >55% or FS >29%.
Results: One hundred and eleven patients were enrolled of whom 32 had abnormal 
cardiac function and were classified as cases while 79 had normal cardiac function. About 
a third, point prevalence 29% (95% CI 21.2-37.9), had cardiac dysfunction. Cumulative 
anthracycline dose was a risk factor for cardiac dysfunction in this population. Above 
200mg/m2 the attributable risk percentage of cardiac dysfunction was 77%.
Conclusions: Serial echocardiography should be performed to identify patients at risk. 
Alternative treatment protocols should be used when the cumulative anthracycline dose 
exceeds 200mg/m2 due to the high attributable risk. Studies to further assess the other 
associated risk factors and long term effects of anthracycline are recommended.
INTRODUCTION
It is estimated that the annual frequency of childhood 
cancers at Kenyatta National Hospital (KNH) is 125 
cases per year. A review of some childhood cancers 
at KNH by Macharia (1), found the hospital based 
prevalence to be 1.27%. The commonest childhood 
cancers were lymphomas (51%), leukaemias (22.3%), 
nephroblastoma (8.5%), rhabdomyosarcoma (5.3%), 
neuroblastoma (3.3%), kaposi’s sarcoma (1.5%), 
ovarian cancers (1.4%) and osteogenic sarcoma 
(1.3%). 
  Cancer chemotherapeutic agents can be 
broadly classified as antibiotics, alkylating agents, 
antimetabolites, natural products and hormones 
agents (2). The two commonly used anthracycline 
antibiotics, daunorubicin and doxorubicin, differ 
only by one hydroxyl group in their biochemical 
structure. Doxorubicin is the main anthracycline 
used at Kenyatta National Hospital (KNH). Their 
anti-cancer activity is due to their ability to inhibit 
nucleic acid synthesis by binding to both parts of the 
deoxyribonucleic acid (DNA) helix thereby blocking 
the normal function of the ribonucleic acid (RNA) 
and DNA polymerase (3). Both the RNA and DNA 
undergo hepatic metabolism and biliary excretion. 
There is rapid uptake by the heart, lungs, kidney 
and spleen but they do not cross the blood brain 
barrier. 
  Anthracycline antibiotics remain one of the most 
potent antineoplastic agents and have contributed 
enormously to the excellent treatment results seen 
in some childhood tumours worldwide (4). They, 
however, do have some unwanted systemic side 
effects.  Anthracycline effects on the heart are probably 
the most well documented causes of morbidity 
and mortality in patients on anthracyclines. Early 
cardiotoxicity occurs during treatment or within 
a year of completion of treatment and can present 
as arrhythmias, ECG changes or left ventricular 
dysfunction. Late cardiotoxicity occurs more than a 
year after completion of treatment and presents as 
cardiomyopathy, pleural effusion, left ventricular 
dysfunction and low output heart failure. Early 
cardiotoxicity is a risk factor for late cardiotoxicity 
that is often not irreversible (3,5,6). 
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 The mechanisms involved in anthracycline 
cardiotoxicity are not fully understood but are thought 
to include production of free radicals derived from 
the chemical reduction of anthracyclines through 
metabolic pathways catalyzed by iron, abnormalities 
in mitochondrial energy metabolism and intracellular 
calcium overload (3). The risk factors for cardiac 
dysfunction in children with malignancies are 
attributed to several factors:
The type of malignancy:  Cancer contributes to cardiac 
dysfunction by several mechanisms, including tumour 
embolization leading to myocardial infarction, direct 
compression, nonbacterial thrombotic endocarditis 
by metastatic cancers or by extension into the great 
veins and cardiac chambers (7).
Radiotherapy:  Early changes due to radiation include 
cytoplasmic damage, capillary injury, Von Willebrand 
factor release and acute inflammatory reaction. 
Chronic changes include cell death, fibroblastic 
proliferation, thickening of pericardium, valvular 
heart disease and arrhythmias (5). These changes often 
lead to a wide range of clinical sequelae including 
acute pericarditis, chronic pericarditis, coronary heart 
disease, myocarditis, valvular defects and conduction 
delays (8).
Table 1
The relative risk of cardiac toxicity at various 
anthracycline cumulative doses 
Cumulative dose  Relative risk (%)





Adapted from Taketomo, C.K., Hodding, J.H., 
Kraus, D.M. Paediatric Dosage Handbook, 13th 
edn. New York: Lexi – Comp’s Drug Reference 
Hand Book, 2006. 
Cumulative anthracycline dose: The relative risk 
of cardiac toxicity increases with increasing 
anthracycline cumulative doses (9). Table 4 shows the 
relative risk of cardiotoxicity at various cumulative 
anthracycline doses. 
Other cardiotoxic drugs: Cyclophosphamide is another 
potentially cardiotoxic drug which causes clinical 
cardiotoxicity when administered in massive doses 
(120 –240 mg/kg over 1 to 4 days) (3). 
 Other additional factors associated with increased 
occurrence of anthracycline cardiotoxicity are pre-
existing cardiac disease, female sex, trisomy 21, black 
race, young age and nutritional status (6,9-13). 
 Various diagnostic procedures are used to test 
for anthracycline induced cardiotoxicity. These 
include history taking and physical examination, 
electrocardiography, echocardiography, angiography 
with radiolabeled antimyosin antibodies, 
angiocardiography and endomyocardial biopsy. 
Each with varying sensitivity and specificity. 
 Some of the strategies used to prevent or limit 
anthracycline cardiotoxicity include early detection 
followed by reductions in anthracycline dose or 
variation of treatment regime. Although serial 
echocardiography monitoring of left ventricular 
function will allow for early identification of 
individuals susceptible to cardiotoxicity and hence 
early intervention, increases in blood, troponin levels 
and myocardial uptake of radiolabeled antimyosin 
antibody are now emerging as the most sensitive 
and specific indicators of myocardial-cell injury (4, 
7). Other strategies to limit or prevent anthracycline 
cardiotoxicity include lowering of peak blood levels 
by variations methods of delivery, for example, 
prolonged continuous infusion rather than by 
bolus injection; lowering of peak dose through 
the use of different treatment schedules or using 
alternative anthracycline derivatives, for example, 
liposomal anthracyclines, may be less cardiotoxic 
than other types of anthracyclines (3). Lipshultz et 
al (17) found dexrazoxane, a trial cardioprotective 
iron chelator, when given to children who were to 
receive doxorubicin was associated with reduction 
in myocardial injury as measures in terms of the 
troponin T level. 
MATERIALS AND METHODS
This study was a descriptive cross-sectional study 
with a nested case control. It was carried out on 
patients admitted at the Kenyatta National Hospital 
(KNH) paediatric oncology, general paediatric and 
ophthalmology wards. KNH is the teaching hospital 
for the University of Nairobi and is also the major 
referral hospital for all paediatric cancer patients in 
Kenya. The study population were children below the 
age of fifteen years with an established diagnosis of 
cancer and on chemotherapy. Patients whose parent 
or guardian did not give consent and re – admissions 
that had been recruited in the study in a previous 
admission were excluded from the study.
 Fischer’s formula was used to determine the 
minimum number of patients as 90, taking into 
account the point prevalence of cardiac dysfunction. 
The sample size for the nested case control was 
determined by using the two sample comparisons 
of proportions for case control studies. A minimum 
number of thirty two cases were required taking a 
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case: control ratio of 2:5, minimum number of cases 
was 32:79 (total 111 patients). 
  Prior diagnosis of cancer in the study group had 
been established using standard methods of bone 
marrow evaluation, fine needle aspirate, tissue biopsy, 
biochemical markers depending on the type of cancer 
supported by various radiological investigations. This 
information was obtained from the patient’s medical 
records. A patient history and general examination 
and was taken. Patient data including anthropometric 
measurements, cumulative anthracycline dose, 
cumulative cyclophosphamide dose and history of 
irradiation were collected. 
  Study patients underwent twelve lead surface 
electrocardiography (ECG) and rhythm strip using 
a manual cardiofax ECG machine, Nihon Kohden 
Corporation.  2-D echocardiography was also 
performed at the cardiology department using an 
echocardiography machine LOGIQ 500 with frequency 
of 33/02.5MH . The modalities of echocardiography 
used were two – dimensional real time, M-mode, 
pulsed wave dopppler and continuous wave Doppler 
echocardiography. 2D-real time echocardiography 
was used to assess the cardiac measurements, 
visual contractility and any abnormal findings like 
pericardial effusion, valvular abnormalities and 
cardiac masses. M-mode echocardiography was used 
to assess the relative chamber sizes and to calculate 
the indices of cardiac contractility. Spectral pulsed 
wave doppler with sample specimen taken at the 
tips of the mitral valve leaflets was used to assess 
diastolic function. Continuous wave doppler was 
used to assess the tricuspid regurgitation. Pulmonary 
pressures were derived from tricuspid regurgitation 
using the Bernoulli’s equation, P = 4V2, where P is the 
pulmonary pressure and V is the maximum velocity 
of the tricuspid regurgitation gradient to estimate the 
pulmonary pressures. 
  To reduce interobserver errors M-mode 
echocardiography investigations were carried out 
separately by a team of three cardiologists using 
a uniform methodical protocol based on the set 
guidelines (8).
  Data was analysed using SPSS (Statistical 
Package for Social Sciences software 11.0). Continuous 
variables were evaluated by t – tests while Pearson chi 
– square tests were used to evaluate binary variables. 
Non-parametric test (Mann Whitney Test) was used 
to evaluate skewed continuous variables. 
RESULTS
During the study period February and May 2006, a 
total of 111 children were evaluated. Their median 
age was six years (Range 0.25-14 years) with 64% of 
them being males and 36% of them being females 
thus a male: female ratio of 1.8:1. Fifty four  per cent 
of the study population were stunted with height/
age Z score less than –2, while 42% had less than 
–2 Z score weight /age. The median duration of 
chemotherapy treatment was four months (Range 
0.25-24 months) 
  Lymphoma was the most common cancer - 31 
(27.5%) patients, followed by leukaemia and Wilm’s 
tumour seen in 25 (23%) and 22 (20%) patients 
respectively. Other less common tumours were 
osteogenic sarcoma and neuroblastoma five (5%) and 
four (3.5%) patients respectively. Other rarer types 
included Kaposi’s sarcoma, and ovarian tumours. 
Table 2 shows the spectrum of cancers seen in the 
study patients. 
 Of the 111 children enrolled 32 had abnormal 
cardiac function and were classified as cases. This 
gave a point prevalence of 29% (95%CI 21.2 – 37.9%). 
The other 79 children with normal cardiac function 
were the controls. The cumulative dose of adriamycin 
used at KNH varied according to the protocol used. 
Table 3 shows the various cumulative anthracycline 
doses set for each type of cancer depending on the 
regimen. The median dose of anthracycline was 
128mg/m2 (Range 0 -500 mg/m2) in cases and 88mg/
m2 (Range 0 - 374 mg/m2) for controls as shown in 
Figure 1. The mean cumulative anthracycline dose 
was 176mg/m2 (95% CI 117.5-211.4 mg/m2) in the 
cases and 106mg/m2 (95% CI 84.1-129.9 mg/m2) in the 
controls. This difference was statistically significant 
at p=0.02. Using percentiles it was shown that above 
a cumulative anthracycline dose of 201mg/m2 there 
was a 4.4 increased odds of cardiac dysfunction with 
an attributable risk percentage of 77%  (Table 4).
Table 2
The spectrum of cancers seen in 111 children
Type of cancer Patients
 No. (%)
Lymphoma
  Burkitt’s lymphoma 19 17
  Hodgkin’s lymphoma 8 7
  Non-Hodgkin’s lymphoma 4 3.5
Leukaemia 25 23
Wilm’s tumour 22 20
Rhabdomyosarcoma 8 7
Retinoblastoma 7 6
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Table 3
The cumulative anthracycline doses for each cancer type according to treatment regimen at KNH 
Malignancy KNH regime KNH regime
 1 cumulative  2 cumulative
 dose dose  
Leukaemia 550 300
Lymphomas
  NHL/BL 440 410
  HL 300 360
Solid tumours 360 420
Wilm’s tumour 250 80
 NHL = Non Hodgkin’s Lymphoma
 BL = Burkitt’s Lymphoma
Figure 1
Box plot showing the cumulative anthracycline dose in the study patients
Key for controls: Key for case:
Minimum dose =0(mg/m2)  Minimum dose(mg/m2) = 0 
25th percentile = 28mg/m2  25th percentile = 41mg/m2
50th percentile= 88 mg/m  50th percentile = 128 mg/m2
75th percentile= 160 mg/m2  75th percentile = 308 mg/m2
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Table 4
Summary of univariate analysis of categorical risk factors for cardiac dysfunction
Variable Category No. Case Control Odd ratio P-value
    (n=32) (n=29) (95%CI)
 
Sex Male 71 22 49 0.7
 Female 40 10 30 (0.3-1.8) 0.7
Age 0 – 3.5 25 8 17 1 -
 3.6 – 7.5 43 13 30 0.9(0.3-2.7) 1.0
 7.6 – 11.5 33 9 24 0.8(0.3-2.9) 0.8
 11.6 – 77.5  10 2 8 0.5(0.1-3.1) 0.7
Nutritional status ≤ 2 60 17 43 1(0.5-2.5) 1.0
Weight/Age ≥ 2 47 14 33 
Nutritional status ≤ 2 51 16 35 0.8(0.4-1.8) 0.7
Height/Age ≥ 2 60 16 44
Type of cancer Leukaemia 25 9 16 1  -
 Lymphoma 31 10 21 0.8(0.3-2.6) 0.8
 Nephroblastoma 22 5 17 0.5(0.1-1.9) 0.4
 Other solid tumours 33 8 25 0.6(0.2-1.8) 0.4
Anthracyclines
Cumulative dose
(mg/m2) 0-30 (up to 25th percentile) 29 5 24 1 -
 30.1-94 (up to 50th percentile) 26 9 17 2.5(0.7-8.9) 0.2
 94.1-201 (up to 75th percentile) 30 6 24 1.2(0.3-4.5) 1.0
 > 201 (> 75th percentile)  25 12 13 4.4(1.3-15.4) 0.02
   
 The median cumulative cyclophosphamide dose 
was 2050mg/m2 (Range 0 - 9363 mg/m2) for cases and 
1510mg/m2 (0-10300 mg/m2) for controls. The mean 
cumulative cyclophosphamide dose was 2880 mg/m2 
(95%CI 1804.0-3515.2 mg/m2) in the cases and 2248 
mg/m2 (95% CI 1758.2-2874.9 mg/m2) in the controls. 
This difference was not significantly associated with 
cardiac dysfunction at p = 0.3 (Table 5). 
  There was no association found between sex 
or nutritional status (Weight/Age or Height/Age) 
and the frequency of cardiac dysfunction. Using the 
youngest age category as a reference, no association 
between age and cardiac dysfunction was seen. 
Using patients with leukaemia as the comparison 
group, no difference in risk for cardiac dysfunction 
by malignancy type was observed. 
DISCUSSION
This study found that the commonest type of cancer 
seen were the lymphomas (28%). This figure was 
less than that found in the study by Macharia (1) 
which found lymphomas to be 51%. The latter study 
however, did not look at retinoblastoma and brain 
tumours which are relatively common cancers in 
childhood. Both studies found Burkitt’s lymphoma 
to be the most common lymphoma making up about 
2/3 of the lymphoma cases. Nephroblastoma was 
also more frequent in our study. 
  Childhood cancers continue to be an important 
area in paediatrics. The harmful side effects of the 
various chemotherapeutic agents versus their useful 
anticancer effects present patient management 
challenges. In long-term survivors, the possible late 
effects of treatment and their consequences for the 
quality of life are a major concern.
  In this study left ventricular function was 
evaluated in a total of 111 paediatric cancer patients. 
The point prevalence for cardiac dysfunction in 
children on treatment for cancer was 29% (95%CI 
21.5-37.9). This represents about a third of the 
patients on treatment and is at a higher frequency 
than previously described (3, 7). The risk of cardiac 
dysfunction or cardiotoxiticy as measured by left 
ventricular dysfunction was related to cumulative 
anthracycline dose. The median duration of therapy 
of four months is an indication of early phase of 
treatment; hence the cardiac dysfunction seen was a 
measure of early anthracycline cardiotoxicity. In this 
study, there was a 4.4 odds of cardiotoxicity above 
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a cumulative dose of 200mg/m2 (Relative Risk 4.4, 
95% CI 1.3-15.4, p-value= 0.02). Previous studies, 
mainly in developed countries, have documented 
the relative risk of cardiotoxicity at cumulative dose 
<300mg/m2 to be between 1-2% (14). This suggests 
increased susceptibility amongst our population. 
It is worth noting that black race has been noted 
to be a risk factor for anthracycline cardiotoxicity. 
This maybe due to perhaps  race related differential 
pharmacogenomics. 
  As shown in other studies, young age at diagnosis 
is one of the strongest predictors of a thin left 
ventricular wall, which leads to an elevated afterload 
in patients treated with anthracyclines (3, 6). Although 
this study did not clearly show age to be a risk factor, 
in the categorical analysis for age, the Odds ratio for 
cardiac dysfunction appeared to be reducing with 
increasing age suggesting that young age may be 
a risk factor for cardiac dysfunction in children on 
treatment for cancer. The linear tend for p-value was 
however not significant. The small number of subjects 
analysed may have been the limiting factor. 
  Based on the study findings, we advocate routine 
serial echocardiography to identify at risk patients. 
Where there is a cumulative anthracycline dose of 
200mg/m2, use of alternative treatment protocols, 
or reduction of the anthracycline dose is suggested. 
Variations of the method of delivery, use of liposomal 
anthracycline, where feasible, are other strategies 
that may be tried. Studies to further assess other risk 
factors associated with cardiotoxicity and the long 
term effects of anthracyclines are recommended.
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